---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059716"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:43:39.200140+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kintara Therapeutics Q3 FY2024 net loss $2.0M ($0.05/sh), cash $6.35M; merger with TuHURA on track

## Summary
- Net loss of $2.0M (diluted EPS -$0.05) vs $3.3M (-$1.94) in prior-year Q3; narrower loss due to lower R&D.
- Cash and equivalents $6.35M at March 31, 2024, up from $1.54M at June 30, 2023.
- R&D expense fell to $0.59M from $2.01M YoY; G&A rose to $1.49M on merger-related professional fees.
- Merger with TuHURA expected to close in Q3 2024; existing stockholders receive contingent value rights tied to REM-001 milestone.
- REM-001 CMBC study expanded to include pembrolizumab patients; $2.0M NIH SBIR grant covers most study costs.

## SEC filing metadata
- accession: 0000950170-24-059716
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017024059716/0000950170-24-059716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017024059716/ktra-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059716
- JSON: https://secwatch.observer/filing/0000950170-24-059716.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059716.txt

## Key facts
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2024 results: net income net loss of approximately $2.0 million, EPS $0.05 per share.
  - Period: fiscal third quarter ended March 31, 2024
  - Net income: net loss of approximately $2.0 million
  - EPS: $0.05 per share
  - Result: reported results
  source text: As of March 31, 2024, Kintara had cash and cash equivalents of approximately $6.35 million. For the three months ended March 31, 2024, Kintara reported a net loss of approximately $2.0 million, or $0.05 per share, compared to a net loss of approximately $3.3 million, or $1.94 per share, for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017024059716/0000950170-24-059716-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.